Estrogen for the Treatment and Prevention of Breast Cancer
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cancer Biology and Oncology".
Deadline for manuscript submissions: closed (30 April 2024) | Viewed by 1682
Special Issue Editor
Special Issue Information
Dear Colleagues,
Estrogen exerts a significant influence on the development of breast cancer, primarily by binding to cellular estrogen receptors (ERs). Breast cancer can be categorized into two subtypes on the basis of the presence of ERs: ER-positive and ER-negative. In hormone receptor-positive (HR+) breast cancer, ERs serve as the principal transcription factors driving oncogenesis and play dual roles as both predictor and target of antiestrogen therapy response. Currently, available anti-estrogen therapies and HER-2 targeted therapies exhibit limited efficacy in the treatment of triple-negative breast cancer (TNBC). In the case of ERα-negative breast cancer, a combination of chemotherapy and molecular-targeted drugs is commonly employed, with potential effectiveness anticipated through immune checkpoint inhibitors. Additionally, hormone therapies may prove efficacious in instances where other hormone receptors such as androgen and glucocorticoid receptors are expressed in ERα-negative breast cancer. The involvement of germline BRCA1/2 mutations in both ER-negative and ER-positive breast cancer pathogenesis is well established; however, numerous unknown factors persist regarding the pathological characteristics, genetic background, and immunological features associated with ERα-negative breast cancer.
Prof. Dr. Virgil Craig Jordan
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- estrogen
- estrogen receptor alpha
- ERα
- breast cancer
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
